Table 3 Results of the cost-effectiveness analysis
From: Economic evaluation of cemiplimab plus chemotherapy regimen for advanced non-small-cell lung cancer
Scenario | Regimen | LYs | QALYs | Cost, US$ | ICER($/LY) | ICUR($/QALY) |
|---|---|---|---|---|---|---|
Scenario1 | placebo plus chemotherapy | 1.3906 | 0.8550 | 54,234.1 | - | - |
cemiplimab plus chemotherapy | 1.9685 | 1.2339 | 204,124.6 | 259,370.9 | 395,593.8 | |
Scenario 2 | placebo plus chemotherapy | 1.3906 | 0.8550 | 54,234.1 | - | - |
cemiplimab plus chemotherapy | 3.1005 | 1.7773 | 228,367.4 | 101,838.3 | 188,803.3 |